CliffBio
small molecule

FOSAPREPITANT DIMEGLUMINE

FOSAPREPITANT DIMEGLUMINE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameFOSAPREPITANT DIMEGLUMINE
Active ingredientFOSAPREPITANT DIMEGLUMINE
StrengthEQ 150MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2019
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.